These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 ("PCSK9"). By its complaint, Amgen seeks an injunction to prevent
Pennsaid 2% is a topical product containing 2% diclofenac sodium compared to 1.5% for original Pennsaid and it is approved in the US to treat pain of osteoarthritis
Currently, DKSH is managing Roche’s entire supply chain operations for pharmaceutical products and distribution to hospitals, clinics and pharmacies in the region. According to DKSH, the agreement will
Imbruvica, which is now approved throughout the 28 European Union (EU) member states, is indicated for CLL patients who have received at least one prior therapy, or in
Embeda is used to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The updated label states that
Anoro Ellipta is a combination of long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA). The 24-week, blinded, parallel group, multicenter trial evaluated the efficacy and safety of
EZH2 is a histone methyltransferase (HMT), which will play a potentially oncogenic role in a number of cancers such as germinal centre (GC) non-Hodgkin lymphomas, INI1-deficient cancers such
The drug has also been designated an orphan drug by the US Food and Drug Administration (FDA) to treat pancreatic cancer and small-cell lung cancer. The company claims
Granted marketing authorization under the trade-name Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The marketing
The company’s ANDA product is a generic version of Pfizer and Tris Pharma’s Quillivant XR, which is a central nervous system (CNS) stimulant indicated to treat attention deficit
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.